ANTX
AN2 Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
AN2 Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
No changes.
No changes.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Annual filing, covered
10-K parsed · Mar 17 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 17 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for AN2 Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for AN2 Therapeutics, Inc..
AN2 Therapeutics, Inc.
4.18
−0.17 · −3.98%
post 4.18 0.00%
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Vivo Capital | $15.3M | 12.83% | 0.00% |
| Commodore Capital | $14.2M | 11.93% | +25.71% |
| Millennium | $11.2M | 9.43% | +4.33% |
| BlackRockindex-like | $8.1M | 6.77% | +422.48% |
| Spruce Street Capital | $8.0M | 6.76% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Vivo Capital | $15.3M | 12.83% | 0.00% |
| Commodore Capital | $14.2M | 11.93% | +25.71% |
| Millennium | $11.2M | 9.43% | +4.33% |
| BlackRockindex-like | $8.1M | 6.77% | +422.48% |
| Spruce Street Capital | $8.0M | 6.76% | 0.00% |
Bull1
Bear2
Expected move
No implied move.